Ryan Iarrobino

412 total citations
9 papers, 181 citations indexed

About

Ryan Iarrobino is a scholar working on Genetics, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ryan Iarrobino has authored 9 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ryan Iarrobino's work include Muscle Physiology and Disorders (5 papers), Neurogenetic and Muscular Disorders Research (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers). Ryan Iarrobino is often cited by papers focused on Muscle Physiology and Disorders (5 papers), Neurogenetic and Muscular Disorders Research (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers). Ryan Iarrobino collaborates with scholars based in United States. Ryan Iarrobino's co-authors include Yung Chyung, Carol L. Clark, Charles S. Graffeo, Howard Klausner, Lawrence M. Lewis, Leslie E. Stolz, James R. Miner, Chris TenHoor, Burt Adelman and Shaun Cote and has published in prestigious journals such as Neurology, Allergy and Annals of Emergency Medicine.

In The Last Decade

Ryan Iarrobino

8 papers receiving 175 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan Iarrobino United States 6 147 59 54 35 33 9 181
Angelica Leccese Italy 7 208 1.4× 88 1.5× 91 1.7× 47 1.3× 45 1.4× 15 290
Henrike Feuersenger United States 10 198 1.3× 46 0.8× 72 1.3× 62 1.8× 58 1.8× 30 233
Anna Valerieva Bulgaria 8 138 0.9× 25 0.4× 45 0.8× 38 1.1× 47 1.4× 25 178
Giorgia Cordisco Italy 7 260 1.8× 57 1.0× 95 1.8× 53 1.5× 58 1.8× 8 292
Inmaculada Martinez Saguer Germany 6 116 0.8× 36 0.6× 26 0.5× 217 6.2× 16 0.5× 11 282
György Temesszentandrási Hungary 8 325 2.2× 50 0.8× 132 2.4× 113 3.2× 76 2.3× 11 375
Angelo Agostoni Italy 7 287 2.0× 42 0.7× 112 2.1× 82 2.3× 66 2.0× 7 355
Sonja Visscher United States 5 250 1.7× 36 0.6× 100 1.9× 74 2.1× 62 1.9× 7 267
George Harmat Hungary 6 267 1.8× 46 0.8× 104 1.9× 79 2.3× 41 1.2× 8 290
Romualdo Vacchini Italy 7 330 2.2× 36 0.6× 174 3.2× 74 2.1× 86 2.6× 8 349

Countries citing papers authored by Ryan Iarrobino

Since Specialization
Citations

This map shows the geographic impact of Ryan Iarrobino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Iarrobino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Iarrobino more than expected).

Fields of papers citing papers by Ryan Iarrobino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan Iarrobino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Iarrobino. The network helps show where Ryan Iarrobino may publish in the future.

Co-authorship network of co-authors of Ryan Iarrobino

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan Iarrobino. A scholar is included among the top collaborators of Ryan Iarrobino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan Iarrobino. Ryan Iarrobino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Crawford, Thomas O., Basil T. Darras, John Day, et al.. (2024). Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3. Neurology. 102(5). e209151–e209151. 19 indexed citations
2.
3.
Barrett, D, Sanela Bilic, Yung Chyung, et al.. (2021). A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy. Advances in Therapy. 38(6). 3203–3222. 30 indexed citations
4.
Barrett, D, Shaun Cote, George G. Nomikos, et al.. (2021). SMA - TREATMENT. Neuromuscular Disorders. 31. S134–S134. 1 indexed citations
5.
Kalra, Ashish, Shaun Cote, D Barrett, et al.. (2019). P.126SRK-015, a fully human monoclonal antibody inhibiting myostatin activation, offers sustained target engagement across multiple species, including humans. Neuromuscular Disorders. 29. S85–S85. 3 indexed citations
6.
Lewis, Lawrence M., Charles S. Graffeo, Howard Klausner, et al.. (2014). Ecallantide for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial. Annals of Emergency Medicine. 65(2). 204–213. 51 indexed citations
7.
Chyung, Yung, Bradley Vince, Ryan Iarrobino, et al.. (2014). A phase 1 study investigating DX-2930 in healthy subjects. Annals of Allergy Asthma & Immunology. 113(4). 460–466.e2. 44 indexed citations
8.
Lumry, William R., Jonathan A. Bernstein, Andrew J. MacGinnitie, et al.. (2013). Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study. Allergy and Asthma Proceedings. 34(2). 155–161. 23 indexed citations
9.
Bernstein, Jonathan A., Elizabeth P. Shea, Juergen Koester, Ryan Iarrobino, & W.E. Pullman. (2012). Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema. Allergy. 67(9). 1173–1180. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angelica Leccese Breakdown of academic impact, for papers by Henrike Feuersenger Breakdown of academic impact, for papers by Anna Valerieva Breakdown of academic impact, for papers by Giorgia Cordisco Breakdown of academic impact, for papers by Inmaculada Martinez Saguer Breakdown of academic impact, for papers by György Temesszentandrási Breakdown of academic impact, for papers by Angelo Agostoni Breakdown of academic impact, for papers by Sonja Visscher Breakdown of academic impact, for papers by George Harmat Breakdown of academic impact, for papers by Romualdo Vacchini
Rankless by CCL
2026